207 related articles for article (PubMed ID: 25870382)
1. Routine use of zoledronic acid in early-stage breast cancer.
Harnden K; Blackwell K
J Natl Compr Canc Netw; 2015 Apr; 13(4):480-6. PubMed ID: 25870382
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.
Huang WW; Huang C; Liu J; Zheng HY; Lin L
PLoS One; 2012; 7(7):e40783. PubMed ID: 22844410
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid: a review of its use in breast cancer.
Lyseng-Williamson KA
Drugs; 2008; 68(18):2661-82. PubMed ID: 19093706
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid in the management of metastatic bone disease.
Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
10. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Gralow J
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S54-62. PubMed ID: 15807925
[TBL] [Abstract][Full Text] [Related]
11. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
Aft R; Naughton M; Trinkaus K; Watson M; Ylagan L; Chavez-MacGregor M; Zhai J; Kuo S; Shannon W; Diemer K; Herrmann V; Dietz J; Ali A; Ellis M; Weiss P; Eberlein T; Ma C; Fracasso PM; Zoberi I; Taylor M; Gillanders W; Pluard T; Mortimer J; Weilbaecher K
Lancet Oncol; 2010 May; 11(5):421-8. PubMed ID: 20362507
[TBL] [Abstract][Full Text] [Related]
12. Breast-cancer adjuvant therapy with zoledronic acid.
Coleman RE; Marshall H; Cameron D; Dodwell D; Burkinshaw R; Keane M; Gil M; Houston SJ; Grieve RJ; Barrett-Lee PJ; Ritchie D; Pugh J; Gaunt C; Rea U; Peterson J; Davies C; Hiley V; Gregory W; Bell R;
N Engl J Med; 2011 Oct; 365(15):1396-405. PubMed ID: 21995387
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
14. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.
Coleman RE; Seaman JJ
Semin Oncol; 2001 Apr; 28(2 Suppl 6):11-6. PubMed ID: 11346860
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?
Gnant M
Curr Oncol Rep; 2012 Feb; 14(1):35-43. PubMed ID: 22113793
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]